JETIR.ORG

# ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

# ALZHEIMER'S DISEASE PREDICTION USING XGBOOST MACHINE LEARNING MODEL WITH SHAP EXPLAINABILITY

# <sup>1</sup>Shaik Javeed, <sup>2</sup>Mrs V Dakshayani

<sup>1</sup>P G Student, <sup>2</sup> Associate Professor

- <sup>1</sup> Dept. of CSE, MJR College of Engineering and Technology, Piler, India
- <sup>2</sup> Dept. of CSE, MJR College of Engineering and Technology, Piler, India

Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that impairs memory, cognition, and behavior. Early diagnosis is vital for timely treatment, yet traditional clinical and neuroimaging methods are often costly and time-consuming. This study proposes an explainable machine learning framework using the Extreme Gradient Boosting (XGBoost) algorithm for accurate and interpretable AD prediction. The dataset includes demographic, lifestyle, medical, and cognitive features such as age, gender, BMI, cholesterol, blood pressure, MMSE score, and behavioral symptoms. Exploratory data analysis and visualizations were performed to identify key patterns and correlations. The XGBoost model achieved high accuracy, precision, recall, F1-score, and ROC-AUC in distinguishing healthy and AD subjects. SHAP (SHapley Additive exPlanations) analysis provided interpretability by identifying the most influential features. The proposed XGBoost–SHAP framework ensures reliable early AD detection and supports personalized clinical decisions.

# I. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that causes memory loss, cognitive decline, and behavioral impairment, primarily affecting older adults. It accounts for about 60–70% of dementia cases worldwide and poses a major global health and economic challenge. According to the World Health Organization, over 55 million people live with dementia, and this number may triple by 2050. AD is marked by amyloid plaques and neurofibrillary tangles in the brain, leading to neuronal death and brain atrophy. Current treatments such as cholinesterase inhibitors and NMDA antagonists offer only temporary relief without halting disease progression, making early detection crucial. The disease arises from multiple factors including age, genetics (e.g., APOE &4), cardiovascular issues, diabetes, obesity, depression, and unhealthy lifestyles.

Traditional diagnostic methods—such as cognitive assessments (MMSE, MoCA), neuroimaging (MRI, PET), and CSF biomarker tests—are effective but costly, invasive, and limited in accessibility. Additionally, overlapping symptoms with other disorders make early diagnosis difficult. Machine Learning (ML) has emerged as a powerful tool in medical diagnosis, capable of identifying hidden patterns in large, complex datasets. Algorithms like Random Forest, Support Vector Machine, and Gradient Boosting have shown strong potential in predicting diseases, including AD. However, most ML models lack interpretability, which is essential for clinical acceptance. To overcome this limitation, Explainable Artificial Intelligence (XAI) methods such as SHAP (SHapley Additive exPlanations) provide transparency by showing how each feature influences model predictions.

This study proposes an interpretable Alzheimer's prediction framework using the Extreme Gradient Boosting (XGBoost) algorithm with SHAP analysis. The model uses demographic, clinical, and cognitive features to classify Healthy and AD subjects accurately while ensuring transparency for clinical decision-making.

# II. LITERATURE SURVEY

Several studies have explored machine learning and deep learning techniques for Alzheimer's disease (AD) detection and diagnosis. N. Chedid et al. developed an automated EEG-based machine learning pipeline using logistic regression with an accuracy of 81%, addressing challenges such as manual preprocessing, large data dependency, and lack of model transparency. Their approach demonstrated the potential for scalable and automated AD diagnosis in clinical settings. O. A. Dara et al. conducted a comprehensive survey of over 80 publications since 2017, highlighting the role of genetic, environmental, and nutritional factors in AD development and emphasizing the value of machine learning and AI-based models in integrating neuroimaging and non-imaging biomarkers for improved diagnosis. Similarly, Isra Malik et al. reviewed 116 research papers across multiple databases, covering deep learning methods, datasets, and feature extraction techniques for AD prediction. The study emphasized the importance of interpretability and explainability in AI-based diagnostic systems to enhance clinical trust. V. Adarsh et al. proposed

a CNN-based multimodal framework integrated with a Multi-feature Kernel Supervised Discriminative Dictionary Learning (MKSCDDL) technique, achieving a remarkable 98.27% accuracy in classifying AD, Mild Cognitive Impairment (MCI), and cognitively normal subjects with transparent decision-making. Likewise, Ghassan Al Rahbani et al. combined ResNet and EfficientNet architectures with post-processing heuristics for multiclass AD detection, enhancing model robustness, interpretability, and diagnostic accuracy. Collectively, these studies demonstrate that explainable machine learning and hybrid deep learning approaches significantly improve early Alzheimer's detection, accuracy, and clinical applicability.

#### III. PROPOSED METHODOLOGY

#### 3.1 Problem Statement

Existing Alzheimer's disease (AD) diagnostic systems primarily rely on clinical evaluations, neuropsychological tests, and neuroimaging techniques such as MRI, PET, and CT scans. While effective, these methods are costly, time-consuming, and invasive, making them unsuitable for large-scale or early screening. Cognitive tools like MMSE and CDR often fail to detect early pathological changes, leading to delayed diagnosis. Machine learning models such as Logistic Regression, SVM, and Random Forest have been applied to improve accuracy, but they struggle to capture complex nonlinear relationships and often rely on small datasets, limiting generalization. Moreover, most deep learning-based models function as black boxes with limited interpretability, which restricts their clinical trust. They also neglect behavioral and lifestyle factors, offering a fragmented view of AD progression. Hence, there is a need for an interpretable, efficient, and holistic diagnostic model that integrates multi-domain data for early detection.

# 3.2 Proposed System

The proposed system introduces a hybrid, data-driven diagnostic framework based on the Extreme Gradient Boosting (XGBoost) algorithm integrated with SHAP (SHapley Additive exPlanations) for transparency. Unlike imaging-based systems, it uses clinical, demographic, behavioral, and physiological features such as age, BMI, cholesterol, MMSE score, and lifestyle factors to provide a cost-effective and comprehensive risk evaluation. The workflow includes data preprocessing (missing value handling and normalization), data splitting (80:20 ratio), model training using XGBoost, and performance evaluation through accuracy, precision, recall, F1-score, and ROC-AUC. SHAP analysis enhances interpretability by quantifying each feature's contribution to predictions, helping clinicians understand the impact of factors like age, MMSE score, and family history on AD risk. This combination ensures a high-performing, explainable, and reliable diagnostic tool.




FIG 1: SYSTEM ARCHITECTURE

# **Proposed Modules:**

The system consists of seven key modules: (1) Data Collection from Kaggle (clinical, demographic, and behavioral features), (2) Data Preprocessing using imputation and MinMax scaling, (3) Data Splitting into training and testing sets, (4) XGBoost Model Training to learn complex patterns, (5) Model Testing to validate generalization, (6) Performance Evaluation through standard metrics and visualization, and (7) SHAP Analysis for feature interpretability. Together, these modules enable efficient learning, robust validation, and transparent prediction of Alzheimer's disease.

# Proposed Algorithm - XGBoost:

XGBoost is an optimized gradient boosting algorithm that combines multiple decision trees to minimize prediction error iteratively. It applies gradient descent and second-order derivatives for faster and more accurate optimization. Regularization (L1 and L2) prevents overfitting, while pruning and subsampling enhance generalization. XGBoost's ability to handle nonlinear relationships, missing data, and large datasets makes it ideal for biomedical prediction tasks. In this study, it is employed to classify subjects as Healthy or AD, providing reliable probabilistic predictions supported by SHAP-based interpretability.

# IV. SOFTWARE AND DOMAIN DESCRIPTION

This project utilizes Python as the primary programming language due to its simplicity and extensive support for machine learning and data analysis. Essential libraries such as NumPy, Pandas, Scikit-learn, TensorFlow, Keras, Matplotlib, and Seaborn are employed for data preprocessing, model training, and visualization. NumPy and Pandas enable efficient data manipulation, Scikit-learn supports classical ML algorithms, while TensorFlow and Keras facilitate deep learning model development. Visualization tools like Matplotlib and Seaborn help interpret results effectively. The project lies within the domain of Data Mining and Machine Learning, focusing on discovering useful patterns and knowledge from large datasets. Data mining integrates methods from databases, statistics, and artificial intelligence to perform classification, clustering, and pattern recognition. Machine learning enhances this process by enabling systems to automatically learn and make predictions from data. The data mining process involves stages such as preprocessing, modeling, testing, and evaluation to ensure accuracy and reliability. By combining these tools and techniques, the system efficiently extracts meaningful insights from complex data and supports intelligent decision-making.

#### 4.1 SYSTEM DESIGN

The system design defines the structure and functionality of the proposed model, ensuring smooth data flow and process interaction. The Data Flow Diagram (DFD) illustrates how input data is processed and transformed into output, showing relationships among processes, data stores, and external entities. The Unified Modeling Language (UML) provides standardized visual models, including Use Case, Class, Sequence, and Activity Diagrams, which represent system behavior and structure. Input design focuses on collecting, validating, and processing user data efficiently while minimizing errors and ensuring ease of use. Output design emphasizes clear and accurate presentation of processed information for effective decision-making. System testing validates system performance through various test types—Unit, Integration, Functional, and System Testing. White Box and Black Box testing approaches ensure both internal logic and external functionality are verified. Finally, User Acceptance Testing confirms that the system meets all functional requirements and operates as expected. The overall testing results ensure reliability, efficiency, and correctness of the system.

# V. EXPERIMENTAL SYSTEMS

MODULE 1- Data Loading and EDA

#### Dataset

	PatientID	Ago	Gender	Ethnicity	EducationLevel	TMB	Smoking	AlcoholConsumption	PhysicalActivity	DietQuality	***	FunctionalAssessment	MemoryCompl
0	4751	73	0	0	2	22.927749	0	13.297218	6.327112	1.347214		6.518877	
1	4752	89	0	0	0	26.627681	0	4.542524	7.619665	0.518767		7.118696	
2	4753	73	0	3	1	17.796882	0	19.555085	7.844988	1.826335	111	5.895077	
3	4754	7.4	1	0	1	33.800817	1	12.209266	8.428001	7.435604	1111	8.965106	
4	4755	89	0	0	0	20.716974	0	18.454356	6.310.461	0.795496		6.045039	
5	4756	86	3.	3	1	30.626886	.0	4.140144	0.211062	1,584922	-111	5.510144	
6	4757	68	0	3	2	38.387622	1	0.648047	9.257695	5.897388		6.062124	
7	4758	75	0	0	1	18.776009	0	13.723826	4.649451	8.341903	-1101	3,401374	
8	4759	72			0	27.833188	0	12.167848	1.531360	6.736882		7 396061	
9	4760	87	0	0	0	35.456302		16.028688	6.440773	8.085019		1.148904	
to	ows x 34 cot	umns											

Dataset shape / Dataset input features / Statistical Analysis


```
df.shape
```


(2149, 34)

#### df.columns

Intles	CHRIST	(Market)	and	2004	25%	50%	15%	F100
Portion#D	2145.0	5625.6	626.587181024204	4751.0	5200.0	5025.0	6362.0	A306.5
Age	2149.0	74 91679478627361	8 590221392749984	90.0	67.8	76.0	85.0	76.5
Gueder	2149.9	0.5062819918248112	0.3080788996325778	0.0	1.1	1.0	1.0	:11
Obokity	2149.6	0.6975337366219045	0.0961277262689G79	0.0	- 0	0.0	1.0.	3.6
fidulation) mel	2149.6	1.266544901143065	0.00/802881289040628	0.0	1.6	14	3.0	.14
IMI	2149.0	27.85889090794788	£2174200913895238	19.80088110	21.01146700	17.12352361	33.868777772	39.99275746
Snotleg	2149.0	8.208000620199162404	1.40703237574076	0.0	17	0.0	1.0	1.1
AlcuhoComonption	2149.0	18.109441799849232	6.757910298122669	8.002933899	£139309509	9.954812376	15 (57938))	19.98939336
Physicallythilly	2149.8	4.920200144071196	2.8671811189330296	8.833656637	2.679626476	6766424262	7 427896620	9:967479413
DetGualty	2189.0	4.9631379136563765	3.999535999906648	0.00930473	2.6866900	8.679067315	7.698034784	9.000315679
SuspGeality	2140.0	7.051081071003084	1.763672949061463	4.00202900	5.462997209	7.115646231	1.062526938	8.999948317
Family Hattery Abriebson	2149.0	8.25221033038622614	0.4343024148949425	0.0	11	84	1.0	1.5
Cardinossissis-Disease	2149.0	8 10425314099081292	8.30142880352649634	0.0	111	8.0	0.0	7.8
Olehetes	2149.6	8 158 NOT/19847624682	8.367969682657977	0.0	111	8.0	0.0	7.8
Organisation	2143.0	8.20010830020646767	8.48001130784363027	0.0	11	9.4	0.0	14
Heathquy	2149.0	8.00000120000085162	0.2000463423797067	.0.0	1.0	8.6	0.0	14
Hypertension	2145 0	8.14890840812479917	8.356979/0988344066	0.0	1.1	1.1	0.0	1.0
Systotic BP	2149.0	134 26477431383438	25.949362110615084	90.0	112.0	1944	157.0	179.8
Olastofic(Id?	2149.6	FR 54783630394664	17 649496210662676	90.0	74.8	914	195.0	116.6
Chalesteroffoni	2188.6	295. 1975 108765-4615	42 54233064939179	160,0003166	198 2529671	205.0064298	343.0310596	799 9913625
Cholesteroll.DI,	2145.9	GH 33594H1851H83	43 388884053432674	50.23870650	67.19579900	173.342593	161.7137326	198.9018851
CholesteroHEL.	2140.0	68 463633141079385	23 12517367785342	20.00343431	35 0000905	59.7682375	70.93804963	19 58032408
Chelesterol Leglymetiles	2149.0	226.20149617949976	161 99672078941967	99.40719362	197 5838224	130.3019635	314.0390482	399.9418616
MMNE	2145.0	14.76613187626638	8.610151282053028	5.505310146	7.167600257	14.44199991	22.16102791	29.68138366
	2149.8	5.088054971155153	2.8527434741712775	a constona.	2.58628995	S. ESAMBETES	2.546901395	9.996-607073


# Data Visualization





MODULE 2 - Data Preprocessing

**Data Cleaning** 



Data Scaling using MinMax Scaler

# MODULE 3 – Data Splitting

Data Splitting – 80:20

Train shape: (1719, 33) Test shape: (430, 33)

# MODULE 4 – XGBoost Model Training

Model training completed!

# MODULE 5 - Model Testing


**Testing Set Prediction Result** 

*** Actu	al vs Predi	cted Results			
Act	tual Label	Predicted Label	Prediction Probability(AD)		
1159		9	0.000457		
1822			0.005930		
978	0	8	0.041175		
759	0	.0	0.005287		
874		9	0.000714		
109	0	0	0.000621		
1177	1	1	0.999171		
259	0	0	0.002463		
1697	8	9	0.000775		
479	1	1	0.997969		
1107		. 0	0.009242		
836	1	1	0.984947		
2868	1	1	0.886231		
78	0	9	0.012005		
231	0	θ	0.009077		
298	Θ	9	0.000507		
1192	1	1	8,899788		
618	1	1	0.947773		
297	0	9	0.005166		
1738		9	0.013179		

The testing phase evaluates the XGBoost model's performance using unseen data. The model generates predicted labels and probability scores indicating Alzheimer's likelihood. Results show clear separation between healthy and AD subjects, with high probabilities (near 1) for Alzheimer's cases and low values (near 0) for healthy individuals. Most predictions accurately match actual labels, confirming strong learning and generalization. The model demonstrates high precision, reliability, and robustness, making it effective for early Alzheimer's detection and clinical decision support.

#### MODULE 6 – Performance Evaluation

Confusion Matrix



The confusion matrix shows that the XGBoost model accurately classified 268 healthy individuals and 144 Alzheimer's patients, with only 9 false positives and 9 false negatives. These results indicate high accuracy, strong sensitivity, and specificity. The model effectively minimizes classification errors and reliably distinguishes between healthy and AD cases. Overall, the confusion matrix confirms the model's robustness and precision, demonstrating its potential as a reliable tool for early Alzheimer's detection.


#### Performance Metrics

tion	Metrics			
8.95	581			
0.9	543			
0.93	43			
0.95	543			
8.99	216			
tion	Report:			
1	precision	recall	f1-score	support
ny	0.9675	0.9675	0.9675	277
AD.	0.9412	0.9412	0.9412	153
ÿ			0.9581	438
/g	0.9543	0.9543	0.9543	438
rufe.	0.0001	B 0001	0.9581	438
	8.95 8.95 8.95 8.95 8.96 tion	8.9581 8.9543 8.9543 8.9543 8.9916 tion Report: precision ny 8.9675 4D 8.9412 Ty	0.9543 0.9543 0.9543 0.9543 0.9916 tion Report: precision recall ny 0.9675 0.9412 0.9412 0.9412 0.9412	8.9581 8.9543 8.9543 8.9916 tion Report: precision recall f1-score ny 8.9675 8.9675 40 8.9412 8.9412 8.9412 ry 8.9543 8.9543 8.9543

The evaluation metrics confirm the high performance and reliability of the proposed XGBoost-based Alzheimer's prediction model. It achieved 95.81% accuracy, with precision, recall, and F1-score all at 0.9543, showing consistent and balanced performance. The ROC-AUC value of 0.9916 indicates excellent separability between healthy and AD cases. Slightly higher precision and recall


for healthy subjects suggest strong overall classification stability. These results validate the model's efficiency, robustness, and suitability as a reliable tool for early Alzheimer's detection.

**ROC Curve** 



The ROC curve illustrates the strong classification ability of the proposed XGBoost-based Alzheimer's prediction model, showing a steep rise toward the top-left corner, which indicates high sensitivity and low false positives. The AUC value of 0.992 confirms near-perfect discrimination between Alzheimer's and healthy cases. This demonstrates the model's robustness, reliability, and excellent balance between sensitivity and specificity, making it a highly effective tool for accurate early detection and clinical decision support in Alzheimer's diagnosis.

# **SHAP Analysis**



The SHAP analysis highlights how each feature influences the XGBoost model's Alzheimer's predictions. Key factors include Functional Assessment, ADL, and MMSE — where lower scores increase disease risk. Memory Complaints and Behavioral Problems also strongly affect outcomes. Overall, the SHAP results confirm that the model is accurate, interpretable, and clinically reliable.

# VI. CONCLUSION

The proposed XGBoost-SHAP model provides an intelligent and interpretable framework for Alzheimer's disease prediction. Using a Kaggle dataset with clinical and behavioral features such as age, BMI, MMSE, and daily activities, the model achieved 95.81% accuracy and an AUC of 0.992, showing excellent classification performance. SHAP analysis identified Functional Assessment, ADL, and MMSE as key predictors, enhancing transparency and clinical trust. Overall, the model proves to be a robust and explainable tool for early Alzheimer's detection and effective clinical decision support.

#### VII. REFERENCES

- [1] Britton, K., Hill, K. C., & Willroth, E. C. (2024). Supporting the well-being of an aging global population: associations between well-being and dementia.
- [2] Cassani, R., Estarellas, M., San-Martin, R., Fraga, F. J., & Falk, T. H. (2018). Systematic review on resting-state EEG for Alzheimer's disease diagnosis and progression assessment. *Disease markers*, 2018(1), 5174815.
- [3] Sarafraz, G., Behnamnia, A., Hosseinzadeh, M., Balapour, A., Meghrazi, A., & Rabiee, H. R. (2024). Domain adaptation and generalization of functional medical data: A systematic survey of brain data. *ACM Computing Surveys*, 56(10), 1-39.
- [4] Xia W, Zhang R, Zhang X, Usman M. A novel method for diagnosing Alzheimer's disease using deep pyramid CNN based on EEG signals. Heliyon. 2023 Mar 24;9(4):e14858.
- [5] Madhav Acharya, Ravinesh C Deo, Xiaohui Tao, Prabal Datta Barua, Aruna Devi, Anirudh Atmakuru, Ru-San Tan, Deep learning techniques for automated Alzheimer's and mild cognitive impairment disease using EEG signals: A comprehensive review of the last decade (2013 2024), Computer Methods and Programs in Biomedicine, Volume 259, 2025, 108506, ISSN 0169-260.
- [6] Malik I, Iqbal A, Gu YH, Al-Antari MA. Deep Learning for Alzheimer's Disease Prediction: A Comprehensive Review. Diagnostics (Basel). 2024 Jun 17;14(12):1281.
- [7] Chedid, N., Tabbal, J., Kabbara, A. *et al.* The development of an automated machine learning pipeline for the detection of Alzheimer's Disease. *Sci Rep* **12**, 18137 (2022).
- [8] Sen SY, Cura OK, Yilmaz GC, Akan A. Classification of Alzheimer's dementia EEG signals using deep learning. Transactions of the Institute of Measurement and Control. 2024;0(0).
- [9] Chen Y, Wang H, Zhang D, Zhang L and Tao L (2023) Multi-feature fusion learning for Alzheimer's disease prediction using EEG signals in resting state. *Front. Neurosci.* 17:1272834.
- [10] Aviles, Marcos, Luz María Sánchez-Reyes, José Manuel Álvarez-Alvarado, and Juvenal Rodríguez-Reséndiz. 2024. "Machine and Deep Learning Trends in EEG-Based Detection and Diagnosis of Alzheimer's Disease: A Systematic Review" *Eng* 5, no. 3: 1464-1484.
- [11] Min-jae Kim, Young Chul Youn, Joonki Paik, Deep learning-based EEG analysis to classify normal, mild cognitive impairment, and dementia: Algorithms and dataset, Neuro Image, Volume 272, 2023.
- [12] Dara, Omer Asghar, Jose Manuel Lopez-Guede, Hasan Issa Raheem, Javad Rahebi, Ekaitz Zulueta, and Unai Fernandez-Gamiz. 2023. "Alzheimer's Disease Diagnosis Using Machine Learning: A Survey" *Applied Sciences* 13, no. 14: 8298.
- [13] Ghassan Al Rahbani, Rani, Anastasia Ioannou, and Tao Wang. 2024. "Alzheimer's Disease Multiclass Detection through Deep Learning Models and Post-Processing Heuristics." *Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization* 12 (1).
- [14] Roncero-Parra, C., Parreño-Torres, A., Sánchez-Reolid, R., Mateo-Sotos, J., & Borja, A. L. (2024). "Inter-hospital moderate and advanced Alzheimer's disease detection through convolutional neural networks." \*Heliyon, 10\*(4), e26298.
- [15] Huggins, C. J., Escudero, J., Parra, M. A., Scally, B., Anghinah, R., Lacerda De Araújo, A. V., Basile, L. F., & Abasolo, D. (2021). "Deep learning of resting-state electroencephalogram signals for three-class classification of Alzheimer's disease, mild cognitive impairment and healthy ageing." \*Journal of Neural Engineering, 18\*(4), 046087.
- [16] Zhao, Yilu and Lianghua He. "Deep Learning in the EEG Diagnosis of Alzheimer's Disease." ACCV Workshops (2014).

- [17] Xiang Zhang, Yihe Wang, Payal Chandak, Zihuai He, Deep Learning for EEG-Based Alzheimer's Disease Diagnosis, Alzheimer's & DementiaVolume 19, Issue S15, e071575, 2023.
- [18] Patil, V., Madgi, M. & Kiran, A. Early prediction of Alzheimer's disease using convolutional neural network: a review. *Egypt J Neurol Psychiatry Neurosurg* 58, 130 (2022).
- [19] Saidjalol Toshkhujaev, Kun Ho Lee, Kyu Yeong Choi, Jang Jae Lee, Goo-Rak Kwon, Yubraj Gupta, Ramesh Kumar Lama, Classification of Alzheimer's Disease and Mild Cognitive Impairment Based on Cortical and Subcortical Features from MRI T1 Brain Images Utilizing Four Different Types of Datasets, Journal of Healthcare EngineeringVolume 2020, Issue 1 3743171
- [20] Mohi ud din dar, Gowhar, Avinash Bhagat, Syed Immamul Ansarullah, Mohamed Tahar Ben Othman, Yasir Hamid, Hend Khalid Alkahtani, Inam Ullah, and Habib Hamam. 2023. "A Novel Framework for Classification of Different Alzheimer's Disease Stages Using CNN Model" *Electronics* 12, no. 2: 469.
- [21] Saroja, P. ., Nalini, N. J. ., & Mahesh, G. . (2023). Classification of Mild Cognitive Impairment with Deep Transfer Learning Approach using CWT based Scalogram Images. *International Journal on Recent and Innovation Trends in Computing and Communication*, 11(8s), 137–143.
- [22] Roberts R, Knopman DS. Classification and epidemiology of MCI. Clin Geriatr Med. 2013 Nov;29(4):753-72. doi: 10.1016/j.cger.2013.07.003. PMID: 24094295; PMCID: PMC3821397.
- [23] Adarsh, V., Gangadharan, G.R., Fiore, U. *et al.* Multimodal classification of Alzheimer's disease and mild cognitive impairment using custom MKSCDDL kernel over CNN with transparent decision-making for explainable diagnosis. *Sci Rep* 14, 1774 (2024).
- [24] Jorge E. Santos Toural, Arquímedes Montoya Pedrón, Enrique J. Marañón Reyes, A new method for classification of subjects with major cognitive disorder, Alzheimer type, based on electroencephalographic biomarkers, Informatics in Medicine Unlocked, Volume 23,2021,100537, ISSN 2352-9148.
- [25] Silvia Basaia, Federica Agosta, Luca Wagner, Elisa Canu, Giuseppe Magnani, Roberto Santangelo, Massimo Filippi, Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks, NeuroImage: Clinical, Volume 21,2019,101645, ISSN 2213-1582.